Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1956PDF: 1567HTML: 344 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2385PDF: 753HTML: 1718 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1269HTML: 359PDF: 784 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2064PDF: 1294HTML: 3485 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1849PDF: 701HTML: 677 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2716PDF: 970HTML: 5494 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
1858PDF: 1321HTML: 244 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2432PDF: 838HTML: 2107 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
1915PDF: 730HTML: 3098 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
1818PDF: 813HTML: 1213 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2122PDF: 763HTML: 1603Figure 1: 159Table 1: 184 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2493PDF: 698HTML: 2280 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1144PDF: 905HTML: 186 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4182PDF: 1677HTML: 1094 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2739PDF: 1530HTML: 215 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3485PDF: 830HTML: 6692 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7179PDF: 2344HTML: 1698Table 1.: 181Table 2.: 197Table 3.: 179Table 4.: 176 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3120PDF: 898HTML: 2922 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1214PDF: 764HTML: 110 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2703PDF: 810HTML: 6491Untitled: 204Untitled: 167Untitled: 163Untitled: 186 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1662PDF: 914HTML: 126 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1751PDF: 686HTML: 2082Untitled: 186Untitled: 137Untitled: 151Untitled: 137Untitled: 144Untitled: 160Untitled: 166 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1469PDF: 482HTML: 137 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1298PDF: 1263HTML: 77 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3738PDF: 722HTML: 1820 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1509PDF: 772HTML: 136 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1660PDF: 540HTML: 255
1 - 47 of 47 items







